Document:

qure_Ex10_1

		
			Exhibit 10.1
		

		
			Execution Version
		

		
			 
		

		
			 
		

		
			uniQure biopharma B.V.
		

		
			Paasheuvelweg 25a
		

		
			1105BP Amsterdam
		

		
			The Netherlands
		

		
			 
		

		
			26 July 2017
		

		
			 
		

		
			VIA E-MAIL AND BY OVERNIGHT COURIER
		

		
			 
		

		
			Chiesi Farmaceutici S.p.A.
		

		
			Via Palermo, 26/A
		

		
			43122 Parma
		

		
			Italy
		

		
			Attention: CEO
		

		
			Copy to: Corporate Development, Head and General Counsel
		

		
			 
		

		
			 
		

		
			Gentlemen:
		

			
	
			
				 1.
			

			
	
			
			Agreement 

		
			I am writing to confirm the terms and conditions on which uniQure biopharma B.V. (“uniQure”) and Chiesi Farmaceutici S.p.A. (“Chiesi”) (together, the “Parties”, each a “Party”) have agreed to terminate the agreement (as better defined below) between them relating to a certain gene therapy product including an AAV5 Vector containing a certain human Factor IX gene (or part thereof) construct for the treatment of hemophilia B in humans (the “Product”).  As part of that agreement, Chiesi has agreed that it will undertake a smooth and orderly transfer, pursuant to the terms of paragraph 5.1 below, of all activities relating to the development or other exploitation of the Product currently being undertaken by Chiesi, to uniQure (the “Transfer”) and that the termination agreement between the Parties relating to Glybera dated 19 April 2017 (the “Glybera Termination Agreement”) will be amended as provided in this letter agreement.
		

		
			

		 

		

			EMEA: 1133572-1

		

		

			 

		

 

		

			Termination of Co-development and License Agreement

		

		

			July 26, 2017

		

		

			Page | 2

		

		

			 

		

		

			
	
			
				 2.
			

			
	
			
			Termination

			
	
			
				 2.1
			

			
	
			
			The Parties have mutually agreed to terminate the Co-Development and License Agreement dated 29 April 2013 between uniQure and Chiesi (the “Agreement”).  Subject to paragraph 2.4 and ‎5.1 of this letter agreement, each Party acknowledges and agrees that the Agreement shall terminate in their entirety and shall be of no further force and effect (the “Termination”), on ___ July 2017 (the “Termination Date”). 

			
	
			
				 2.2
			

			
	
			
			Chiesi hereby represents and warrants to uniQure that, to its knowledge and as of the Termination Date, no Chiesi Technology is incorporated into the Product, or is required for the development, manufacture, commercialisation or other exploitation of the Product in or outside the Territory (the “IP Warranty”).  Chiesi hereby absolutely, unconditionally and irrevocably, covenants and agrees to uniQure, its Affiliates and its and their licensees, assigns and successors in interest (each a “uniQure Party”) that Chiesi will not and it will procure that its Affiliates and licensees will not, directly or indirectly, assert any Chiesi Technology or bring, initiate, continue, maintain or issue any claim, cause of action or proceeding (at law, in equity, in any regulatory proceeding or otherwise) against any uniQure Party, whether as a claim, cross-claim, counterclaim or otherwise, in each case with respect to the development, manufacture, commercialisation or any other exploitation of the Product by any uniQure Party in or outside the Territory, except to the extent uniQure breaches Section 6.2 of this letter agreement (each such claim, cause of action or proceeding, a “Released Claim”).  If Chiesi breaches this Section ‎2.2 by bringing, initiating, continuing, maintaining or issuing any Released Claim, then Chiesi shall indemnify such uniQure Party against all Losses it incurred in defending such Released Claim, except to the extent uniQure breaches Section 6.2 of this letter agreement (the “IP Indemnity”). Each uniQure Party is a beneficiary to the provisions of this Section 2.2 and is entitled to the rights and benefits hereunder and may enforce such provisions as if it were a party under this letter agreement, except for uniQure’s and its Affiliates’ licensees which may only enforce such provisions through uniQure.   

			
	
			
				 2.3
			

			
	
			
			For the avoidance of doubt and except to the extent uniQure breaches Section 6.2 of this letter agreement, if there is a breach of the IP Warranty: (a) uniQure shall not have a right to recover any Losses incurred as a result of such breach under the IP Warranty, to the extent any uniQure Party has been fully compensated for such Losses under the IP Indemnity, and (b) no uniQure Party shall have a right to be compensated for any Losses incurred as a result of such breach under the IP Indemnity, to the extent uniQure has fully recovered such Losses under the IP Warranty.  

			
	
			
				 2.4
			

			
	
			
			The following terms of the Agreement shall survive the termination of the Agreement on the Termination Date:  Article 1, Section 6.1 (subject to the terms of Section 12.5(i)), Section 7.2, Section 7.3, Section 9.1, Section 10.1, Section 10.2, Section 10.7, Section 11.5, Sections 12.5(a), 12.5(h), 12.5(i); Article XIII, Article XIV, and Article XV. For the avoidance of doubt, all other terms, provisions, rights and obligations under the Agreement are, and shall be deemed to be, terminated and of no further force or effect as of the Termination Date. 

			
	
			
				 3.
			

			
	
			
			Payments

			
	
			
				 3.1
			

			
	
			
			As a full and final settlement of all sums owed and payable by Chiesi to uniQure under Article VIII of the Agreement (excluding the amounts due in invoice number 2017.3007 dated May 1, 2017 for EUR ** (** Euros) invoice number 2017.3004-b dated July 25, 2017 for EUR ** (** Euros) provided to Chiesi by uniQure, which notwithstanding paragraph 6.2 of this letter agreement, Chiesi will pay in accordance with the Agreement) Chiesi shall owe EUR ** (** Euros) to uniQure to be satisfied in accordance with paragraph 3.2 of this letter agreement. 

		
			

		 

 

		

			Termination of Co-development and License Agreement

		

		

			July 26, 2017

		

		

			Page | 3

		

		

			 

		

		

			
	
			
				 3.2
			

			
	
			
			The parties agree that the Base Amount, the Patient 1 Amount and the Patient 2 Amount (each as defined in the Glybera Termination Agreement) shall be due as of the Termination Date and that Chiesi shall be entitled to withhold EUR ** (** Euros) from the amount otherwise payable pursuant to paragraph 3.1 of this letter agreement. For the avoidance of doubt, as a result of such set off, Chiesi hereby waives and releases uniQure in full from any further payment obligations of uniQure with respect to the Base Amount, the Patient 1 Amount and Patient 2 Amount. Chiesi shall pay the balance of the amount due to uniQure (EUR **), (** Euros) without any deduction, to the bank account specified by uniQure within 15 (fifteen) days of the Termination Date and after having received from uniQure one (1) final invoice for the remaining period till the Termination Date pursuant to the form attached as Exhibit 3 hereto.

			
	
			
				 3.3
			

			
	
			
			All amounts due under this Section 3 are exclusive of any Value Added Tax (which, if applicable, shall be payable by Chiesi in addition to such amounts due upon receipt of a valid Value Added Tax invoice).  All amounts due under this Section 3 shall be made without any deduction or withholding for or on account of any tax unless such deduction or withholding is required by Applicable Laws, in which case the sum payable by Chiesi shall be increased to the extent necessary to ensure that, after the making of such deduction or withholding, uniQure receives and retains (free from any liability in respect of any such deduction or withholding) a net sum equal to the sum it would have received had no such deduction or withholding been made or required to be made.  If uniQure subsequently receives a credit for such deduction or withholding it shall forthwith pay the amount of such credit to Chiesi.  No credit shall have been received by uniQure unless it shall have relieved uniQure of a present obligation to pay tax.

			
	
			
				 4.
			

			
	
			
			Glybera Termination Agreement 

			
	
			
				 4.1
			

			
	
			
			Each Party acknowledges and agrees that, with effect from the Termination Date, the Glybera Termination Agreement is amended as follows:

			
	
			
				 (a)
			

			
	
			
			subparagraph 3 of the third paragraph of Section 3 of the Glybera Termination Agreement shall be deleted in its entirety, such that the Additional Patient Amount (as defined in the Glybera Termination Agreement) shall no longer apply and

			
	
			
				 (b)
			

			
	
			
			the phrase “and Additional Patient Amount” shall be deleted in its entirety from subparagraph 5 of the fourth paragraph of Section 3 of the Glybera Termination Agreement. 

			
	
			
				 5.
			

			
	
			
			Handover

			
	
			
				 5.1
			

			
	
			
			 

			
	
			
				 (a)
			

			
	
			
			The following provisions shall apply to the Termination, it being understood an agreed that all information, documents, materials, records, including Product Data and Product Information, to be provided or transferred by Chiesi hereunder will be provided or transferred on a “as is” basis and without giving any warranty, express or implied, on the status, merchantability, fitness for a particular purpose and non-infringement thereof:

			
	
			
				 (i)
			

			
	
			
			Exhibit 1 attached hereto contains a fair and reasonably accurate description of the status of Development Program activities conducted by Chiesi before the Termination Date and a list of documents generated thereunder (the “Documents List”);

			
	
			
				 (ii)
			

			
	
			
			Chiesi hereby assigns to uniQure the entire right, title and interest in and to, any Product Data in Chiesi’s or its Affiliates’ or Third Party contractors’ possession or Control;

		
			

		 

 

		

			Termination of Co-development and License Agreement

		

		

			July 26, 2017

		

		

			Page | 4

		

		

			 

		

		

			
	
			
				 (iii)
			

			
	
			
			within thirty (30) days after the Termination Date, Chiesi shall assign, on a “as is” basis and without giving any warranty, express or implied, on the status, validity and enforceability thereof, the agreement titled “ACCORDO UNILATERALE DI CONFIDENZIALITÀ” entered into with Professor Carlo Ferrari on January 7, 2015 to uniQure (the “Third Party Agreement”), a copy of which is attached hereto as Exhibit 2; and  

			
	
			
				 (iv)
			

			
	
			
			each Party acknowledges and agrees that, with effect from the Termination Date, for the purposes of Article X of the Agreement:

			
	
			
				 (1)
			

			
	
			
			all Know-How with respect to the Product or the Development Program (including the Product Data, and other Know-How contained in the notes, records, minutes, documents, reports, records, dossiers, correspondence or material (as applicable) described in Sections 5.1(b), (c) or (d)), and the terms and conditions of the Third Party Agreement) (together, the “Product Information”), shall be deemed to be the Confidential Information of uniQure (and for the avoidance of doubt, shall not be the Confidential Information of Chiesi), and the terms and conditions of this letter agreement shall be the Confidential Information of each Party; and

			
	
			
				 (2)
			

			
	
			
			Sections 10.1 (a), (b) and (d) of the Agreement shall not apply with respect to the Product Information generated by Chiesi or the terms and conditions of this letter agreement;

			
	
			
				 (b)
			

			
	
			
			within thirty (30) days after the Termination Date, Chiesi shall destroy and certify in writing to uniQure that it has destroyed  all materials and records in its possession or Control containing Confidential Information of uniQure (including Product Information), except for a single copy of such Confidential Information that may be retained confidentially for legal purposes only; it is however understood and agreed that in the event Chiesi discovers, within one (1) year after the Termination Date, any other materials and/or records containing Confidential Information of uniQure (including Product Information), the provisions of this sub-paragraph (b) shall seamlessly apply.  

			
	
			
				 (c)
			

			
	
			
			within thirty (30) days after the Termination Date, Chiesi shall provide uniQure full access (with rights to download all documents) to the Sharepoint or other network drive containing all notes, records, minutes and documents with respect to all JSC meetings, JDC meetings and JCC meetings, copies of Product Data not previously provided to uniQure and copies of the documents referenced to in the Documents List and shall maintain such access for a period of one (1) month after such full access is granted to uniQure; 

			
	
			
				 (d)
			

			
	
			
			within thirty (30) days after the Termination Date, Chiesi shall transfer to uniQure copies of any market research reports under Chiesi’s or its Affiliates’ or Third Party contractors’ possession or Control with respect to the Products, and transfer to uniQure all copies of the notes, records, dossiers and other documents prepared for or with respect to any meeting with the Regulatory Authorities (including the EMA and any Health Technology Assessments) with respect to the Product under Chiesi’s or its Affiliates’ possession or Control to the extent not already provided to uniQure pursuant to paragraph (c) above;

			
	
			
				 (e)
			

			
	
			
			from the Termination Date, as between uniQure and Chiesi, uniQure shall have the sole right to prepare, obtain and maintain Regulatory Approvals, and to conduct communications with the Regulatory Authorities, in respect to the development, manufacture, commercialisation and other exploitation of the Product (such activities, the “Regulatory Activities”).  Chiesi shall promptly provide (and in any event, no later than five (5) Business Days of receipt) copies of 

		 

 

		

			Termination of Co-development and License Agreement

		

		

			July 26, 2017

		

		

			Page | 5

		

		

			 

		

	any written or electronic correspondence relating to the development, manufacture, commercialisation and other exploitation of the Product which Chiesi or its Affiliates received from the Regulatory Authorities; 

			
	
			
				 (f)
			

			
	
			
			Chiesi shall ensure that those of Chiesi’s employees whose decisions or inputs are reasonably necessary for the activities necessary to enable the Transfer are available to uniQure, during one teleconference to be held within thirty (30) days after the Termination Date, to respond to any of uniQure’s queries on any matter relating to the Transfer, provided that uniQure has sent to Chiesi any such written questions upon the Termination Date; and  

			
	
			
				 (g)
			

			
	
			
			Chiesi shall within thirty (30) days after the Termination Date execute and deliver, or procure any necessary third party shall  within thirty (30) days after the Termination Date execute and deliver, any documents as may be necessary to enable the Transfer.

			
	
			
				 6.
			

			
	
			
			Release of the Parties

			
	
			
				 6.1
			

			
	
			
			Release of the uniQure Released Parties. Effective as of the Termination Date, Chiesi, on behalf of itself and each of its agents, principals, officers, directors, employees, stockholders, partners, parents, subsidiaries, affiliates, predecessors, successors, representatives, and assigns ("Chiesi Affiliates"), fully, finally and forever releases relinquishes and discharges uniQure and any acquirer or assignee of uniQure's assets and their respective past, present or future officers, directors, shareholders, joint venturers, affiliates, members, partners, partnerships, principals, parent companies, subsidiaries, representatives, employees, servants, and agents, in their capacities as such (collectively, the "uniOure Released Parties"), of and from any and all charges, complaints, claims, liabilities, obligations, promises, agreements, controversies, damages or causes of action, suits, rights, demands, costs, losses, debts and expenses (including attorneys' fees and costs incurred) of any nature whatsoever, in law or in equity, whether known or unknown, anticipated or unanticipated, and whether accrued or hereafter to accrue that they now have, may have, or could have from the beginning of time to the Termination Date that in any way arises out of, are connected with, or that are in any way related to, the Agreement, excluding only claims for breach of this letter agreement and the provisions, rights and obligations of the parties that expressly survive the Termination Date as set forth in this letter agreement.

			
	
			
				 6.2
			

			
	
			
			Release of the Chiesi Released Parties. Effective as of the Termination Date, uniQure, on behalf of itself and each of its agents, principals, officers, directors, employees, stockholders, partners, parents, subsidiaries, affiliates, predecessors, successors, representatives, and assigns ("uniQure Affiliates"), fully, finally and forever releases relinquishes and discharges Chiesi and any acquirer or assignee of Chiesi's assets and their respective past, present or future officers, directors, shareholders, joint venturers, affiliates, members, partners, partnerships, principals, parent companies, subsidiaries, representatives, employees, servants, and agents, in their capacities as such (collectively, the "Chiesi Released Parties"), of and from any and all charges, complaints, claims, liabilities, obligations, promises, agreements, controversies, damages or causes of action, suits, rights, demands, costs, losses, debts and expenses (including attorneys' fees and costs incurred) of any nature whatsoever, in law or in equity, whether known or unknown, anticipated or unanticipated, and whether accrued or hereafter to accrue that they now have, may have, or could have from the beginning of time to the Termination Date that in any way arises out of, are connected with, or that are in any way related to, the Agreement, excluding only claims for breach of this letter agreement and the provisions, rights and obligations of the parties that expressly survive the Termination Date as set forth in this letter agreement.

		
			

		 

 

		

			Termination of Co-development and License Agreement

		

		

			July 26, 2017

		

		

			Page | 6

		

		

			 

		

		

			
	
			
				 7.
			

			
	
			
			Public Announcements

			
	
			
				 7.1
			

			
	
			
			Subject to Sections ‎7.2 and ‎7.3 of this letter agreement, neither Party may issue any announcement, press release or make any such other public statement, in each case, with respect to or in connection with the Termination or this letter agreement, without consent of the other Party.  The Parties shall consult together on the timing, contents and manner of release of any such announcement, press release or public statement. 

			
	
			
				 7.2
			

			
	
			
			The Parties agree to make an announcement with respect to the Termination, in the form set out in the Appendix, within two (2) Business Days of the Termination Date (the “Announcement”).  Thereafter, each Party may, without consultation or consent from the other Party, make any public statement in response to questions from the press, research analysts, investors or those attending industry conferences, make internal announcements to employees and make disclosures in documents filed by uniQure with the SEC, so long as such statements, announcements and disclosures substantially reiterate the Announcement or the information within it, and are not inconsistent with the Announcement.   

			
	
			
				 7.3
			

			
	
			
			Where an announcement, press release or public statement is required by Applicable Laws, any Regulatory Authority or governmental authority (including the SEC), or by any court or other authority of competent jurisdiction, the Party required to make such announcement, press release or public statement shall promptly notify the other Party, it shall consult with the other Party about, and shall use its best reasonable efforts to provide the other Party time to comment on, such release or announcement in advance of such issuance, and the required Party will consider such comments in good faith.

			
	
			
				 8.
			

			
	
			
			Interpretation

			
	
			
				 8.1
			

			
	
			
			Capitalised terms not otherwise defined in this letter agreement shall have the meaning set out in the Agreement.

			
	
			
				 8.2
			

			
	
			
			Section 1.130 (a), (b), (c), (d), (e), (f), (g), (h) and (k) of the Agreement shall be incorporated into this letter agreement by reference, with the necessary changes made.

			
	
			
				 9.
			

			
	
			
			Execution as a Deed

			
	
			
				 9.1
			

			
	
			
			Chiesi and uniQure agree that this letter agreement shall be a deed.

			
	
			
				 10.
			

			
	
			
			Other Provisions

			
	
			
				 10.1
			

			
	
			
			Article XV of the Agreement shall be incorporated into this letter agreement by reference.

		
			This document is hereby executed by each of the Parties as a deed and is delivered and takes effect on the date executed by Chiesi.
		

		
			 
		

		
			

		 

 

		

			Termination of Co-development and License Agreement

		

		

			July 26, 2017

		

		

			Page | 7

		

		

			 

		

UNIQURE BIOPHARMA B.V.
		

		
			Executed as a deed by uniQure Biopharma B.V., a company incorporated in the Netherlands, by the following persons, each being a person who, in accordance with the laws of the Netherlands, is acting under the authority of the company.
		

		
			 
		

		
			 
		

		
			By: /s/ Matthew Kapusta
		

		
			Name:Mr. Matthew Kapusta
		

		
			Title:CEO
		

		
			 
		

		
			By: /s/ Christian Klemt
		

		
			Name:Mr. Christian Klemt
		

		
			Title: Global Controller
		

		
			Date: 26/07/2017
		

		
			

		 

 

		

			Termination of Co-development and License Agreement

		

		

			July 26, 2017

		

		

			Page | 8

		

		

			 

		

Chiesi hereby acknowledges and agrees to any and all of the terms set out in this letter agreement and hereby executes and delivers this agreement as deed.  
		

		
			 
		

		
			 
		

		
			Chiesi Farmaceutici S.p.A.
		

		
			Executed as a deed by Chiesi Farmaceutici S.p.A, a company incorporated in Italy, by the following persons, each being a person who, in accordance with the laws of Italy, is acting under the authority of the company.
		

		
			 
		

		
			 
		

		
			By: /s/ Ugo Di Francesco
		

		
			Name: Mr. Ugo Di Francesco
		

		
			Title: CEO
		

		
			 
		

		
			 
		

		
			By: /s/ Paolo Chiesi
		

		
			Name: Mr. Paolo Chiesi
		

		
			Title: Vice President
		

		
			 
		

		
			 
		

		
			

		 

 

		

			Termination of Co-development and License Agreement

		

		

			July 26, 2017

		

		

			Page | 9

		

		

			 

		

		

		
			APPENDIX
		

		
			Form of Press Release 
		

		
			 
		

		
			 
		

		
			uniQure Reacquires Development and Commercialization Rights 
		

		
			for its Gene Therapy Candidate in Hemophilia B 
		

		
			 
		

		
			~ Company now owns full global rights to late-stage program with clinical proof-of-concept ~
		

		
			 
		

		
			 
		

		
			Lexington, MA and Amsterdam, the Netherlands, July ___, 2017 — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has entered into an agreement with Chiesi Group to reacquire the rights to co-develop and commercialize its hemophilia B gene therapy in Europe and other select territories and to terminate their co-development and license agreement.    
		

		
			 
		

		
			“We are very pleased to reach an agreement with Chiesi to acquire back European and other territorial rights to our lead gene therapy program in hemophilia B,” stated Matthew Kapusta, Chief Executive Officer of uniQure.  “By regaining unencumbered, global rights to a late-stage program that has demonstrated significant clinical benefit for patients with hemophilia B, we believe uniQure is better positioned to accelerate the global clinical development plan, maximize shareholder return on our pipeline and take advantage of new potential opportunities related to the program. We are grateful for the substantial investments that Chiesi has made in AMT-060, and we have been fortunate to have them as a collaboration partner over the years.” 
		

		
			 
		

		
			“We have recently made significant progress in preparing for a late-stage clinical program in hemophilia B and will be providing several updates throughout the second half of this year,” added Mr. Kapusta.  
		

		
			 
		

		
			“Chiesi’s decision was driven by recent changes in our strategic priorities,” stated Ugo Di Francesco, Chief Executive Officer of Chiesi.  “We greatly appreciate the advances uniQure has made in the development of AMT-060 over the years and sincerely wish them the best as they advance this potentially exciting gene therapy to patients.  We will continue to support the transition and expect it will be relatively quick and seemless.”
		

		
			 
		

		
			In 2013, uniQure and Chiesi entered into an agreement for the co-development and commercialization of a hemophilia B gene therapy in Europe and other select territories, including an equal sharing of all development related costs.  Under the terms of the agreement announced today, uniQure will be responsible for all future development costs related to its hemophilia B program, including approximately $3 million of expenses in 2017 that would have otherwise been shared with Chiesi.  The Company does not expect the transaction will impact its previous cash guidance, and continues to anticipate cash on hand will be sufficient to fund operations into 2019.
		

		
			 
		

		
			As a result of the transaction, uniQure expects to recognize in the third quarter of 2017 the remaining deferred revenue of approximately $14 million from non-refundable payments received from Chiesi in 2013.   
		

		
			 
		

		
			

		 

 

		

			Termination of Co-development and License Agreement

		

		

			July 26, 2017

		

		

			Page | 10

		

		

			 

		

		

		
			About uniQure 
		

		
			 
		

		
			uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and cardiovascular diseases. www.uniQure.com
		

		
			 
		

		
			About Chiesi Group
		

		
			Based in Parma, Italy, Chiesi Farmaceutici is an international research-focused Healthcare Group, with over 80 years of experience in the pharmaceutical industry, present in 26 countries. Chiesi researches, develops and markets innovative drugs in the respiratory therapeutics, specialist medicine and rare disease areas. Its R&D organization is headquartered in Parma (Italy), and integrated with 6 other key R&D groups in France, the USA, the UK, Sweden and Denmark to advance Chiesi's pre-clinical, clinical and registration programmes. Chiesi employs nearly 5,000 people.
		

		
			 
		

		
			uniQure Forward-Looking Statements
		

		
			 
		

		
			This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the future development of our hemophilia B program, the transition of development efforts from Chiesi and the risk of cessation, delay or lack of success of any of our ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with corporate reorganizations and strategic shifts, collaboration arrangements, our and our collaborators’ clinical development activities, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure’s 2016 Annual Report on Form 10-K filed on March 15, 2017. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.
		

		
			 
		

		
			

		 

 

		

			Termination of Co-development and License Agreement

		

		

			July 26, 2017

		

		

			Page | 11

		

		

			 

		

uniQure Contacts: 
		

		
			 
		

		
			Maria E. CantorTom Malone
		

		
			Direct: 339-970-7536Direct:  339-970-7558
		

		
			Mobile:  617-680-9452Mobile:  339-223-8541
		

		
			m.cantor@uniQure.com t.malone@uniQure.com
		

		
			 
		

		
			 
		

		
			Eva M. Mulder
		

		
			Direct: +31 20 240 6103
		

		
			Mobile: +31 6 52 33 15 79 
		

		
			e.mulder@uniQure.comqure_Ex10_2

		
			Exhibit 10.2
		

		
			 
		

		
			 
		

			
					
						 

				
	
					
						employment AGREEMENT PURSUANT TO SECTION 7:610 (et seq.) of the Dutch Civil Code (DCC)

				
	
					
						August 4, 2017

				

		
			 
		

		
			Employment agreement between
		

			
	
			
				 (1)
			

			
	
			
			uniQure biopharma B.V., a company with limited liability (besloten vennootschap met beperkte aansprakelijkheid), with registered office at Amsterdam and principal place of business at Paasheuvelweg 25a, (1105 BP) Amsterdam (the Employer); and

			
	
			
				 (2)
			

			
	
			
			Sander van Deventer born on __________, residing at the address ________________ (the Employee)

		
			each “a Party”, collectively, “the Parties”.
		

		
			The Parties agree as follows:
		

			
	
			
				 1
			

			
	
			
			Commencement date Agreement and position

			
	
			
				 1.1
			

			
	
			
			Effective August 7, 2017,  this employment agreement (the “Agreement”) will become effective and Employee shall assume a  part-time  (50%), 0.5 FTE, position with the Employer in the position of Chief Scientific Officer and General Manager, Netherlands.  Employee undertakes to perform all the activities as set out in Exhibit A and that can reasonably be assigned to him by or on behalf of the Employer and which are related to the Employer's business. To the best of his ability in doing so, the Employee will comply with the instructions given to him by or on behalf of the Employer.

		
			 
		

			
	
			
				 1.2
			

			
	
			
			The Employee hereby resigns as a member of the Board of Directors of uniQure N.V., subject to and effective upon the appointment of his successor director at an extraordinary general meeting of shareholders of uniQure N.V. to be held on or about 14 September 2017.

			
	
			
				 1.3
			

			
	
			
			The Employer shall be entitled to assign other duties than the usual activities of the Employee, or to alter the position of the Employee if in the reasonable opinion of the Employer the business circumstances so require.

		
			 
		

			
	
			
				 1.4
			

			
	
			
			The Employee shall not be engaged in any business activity which, in the judgment of the Employer, conflicts with Employee’s ability to carry out his duties for the Company, whether or not such activity is pursued for pecuniary advantage,  without the approval of the Board of Directors of uniQure N.V,  other than business activities undertaken in his capacity as a general partner or venture partner of Forbion Capital Partners or its affiliated funds for up to 50% of his time. It is the mutual understanding that  the Employee will resign as Managing Partner of Forbion Capital Partners by no later than June 30, 2018, it being understood that the Employee will thereafter continue as a venture partner or similar function with Forbion Capital Partners or its affiliated funds for up to 50% of his time.

		
			 
		

		
			

		 

 

		

			
	
			
				 1.5
			

			
	
			
			The work will be performed at the office of the Employer at Paasheuvelweg 25a (1105 BP) in Amsterdam provided, however, that the Employee shall be required to travel from time to time for business purposes. The Employer reserves the right to change the location where the work is performed after consultation with the Employee.

		
			 
		

			
	
			
				 1.6
			

			
	
			
			The normal working hours for a full-time, 1.0 FTE position are 40 hours per week. The working hours are normally 8.5 hours a day with a 30 minute lunch break.

		
			 
		

			
	
			
				 2
			

			
	
			
			Term and termination Agreement

			
	
			
				 2.1
			

			
	
			
			The Agreement has been entered into for an indefinite period of time.

			
	
			
				 2.2
			

			
	
			
			The Agreement will in any event, without notice being required, terminate as of the first day of the month following the date the Employee reaches the State pension age (AOW-gerechtigde leeftijd).

			
	
			
				 2.3
			

			
	
			
			The Agreement can be terminated by each of the Parties with due observance of the statutory notice period of 4 months for the Employer and 2 months for the Employee.

			
	
			
				 3
			

			
	
			
			Salary, bonus, equity and holiday allowance

			
	
			
				 3.1
			

			
	
			
			The Employee’s annual salary will be EUR 200,000 gross based on 0.5 FTE, including an 8% holiday allowance. The salary, excluding the holiday allowance, shall be paid in 12 equal,  monthly instalments of EUR 15,432.10. 

			
	
			
				 3.2
			

			
	
			
			Once per year, in the month May, the Employer shall pay to the Employee the holiday allowance of 8% of the annual gross salary earned with the Employer in the preceding calendar year. If the Agreement commences and/or terminates during the calendar year, and/ or the Employee works on a part-time basis, the holiday allowance will be paid out pro rata.

			
	
			
				 3.3
			

			
	
			
			The Employee shall be eligible to a bonus payment amounting to a maximum of 40% of his annual gross salary. The Employee’s eligibility for  a bonus payment shall be dependent on the company guidelines and is at the discretion to the Board of Directors and shall be pro-rated as appropriate to reflect a start date which is not January 1st.

			
	
			
				 3.4
			

			
	
			
			Bonus payments, if any, will not be taken into account for the calculation of any possible severance payment upon termination of the Agreement. Employee needs to be in service on date of bonus pay out.

			
	
			
				 3.5
			

			
	
			
			Subject to Board of Directors’ approval at the next regularly scheduled uniQure N.V. Board meeting after execution of this Agreement, the Employee shall be granted an option to purchase 150,000  (one hundred fifty thousand thousand) ordinary shares of uniQure N.V., the terms of which shall reflect the standard vesting and other terms and conditions contained in the uniQure N.V.’s Amended and Restated 2014 Share Incentive Plan. Such options will be approved by the Board of Directors of uniQure N.V. not later than at its next regularly scheduled meeting and the exercise price will be the closing share price on the grant date. The Executive will be eligible for future equity grants pursuant to the Company’s policies and procedures, which shall also be subject to pro-ration related to the Employee’s part-time status and the employment start date.

		
			

		 

 

		

			
	
			
				 4
			

			
	
			
			Overtime

		
			The Employee undertakes to work overtime at the request of the Employer. The Employer does not pay any compensation for overtime. 
		

			
	
			
				 5
			

			
	
			
			Expenses

			
	
			
				 5.1
			

			
	
			
			The costs for travelling from home to office shall be compensated in accordance with the company policy.

			
	
			
				 5.2
			

			
	
			
			To the extent that the Employer has given prior approval for business travels, the Employer shall reimburse reasonable travel and accommodation expenses relating to such business travel incurred by the Employee in the performance of his duties upon submission of all the relevant invoices and vouchers within 30 days following completion of the business travel.  

			
	
			
				 6
			

			
	
			
			Holidays

			
	
			
				 6.1
			

			
	
			
			The Employee is entitled to 30 business days holiday per year or a pro rata portion thereof if the Agreement commences and/or terminates during the calendar year and/or the Employee works part-time. 

			
	
			
				 6.2
			

			
	
			
			The statutory holiday days (20 days of the 30 per year on full time employment) shall be forfeited after 6 months after the end of the year in which the holiday days were accrued.

			
	
			
				 6.3
			

			
	
			
			The Employer shall determine the commencement and the end of the holiday in consultation with the Employee. The Employee shall take his holidays in the period that the activities best allow this.

			
	
			
				 7
			

			
	
			
			Illness

		
			In the event of illness in the sense of section 7:629 Dutch Civil Code, the Employee must report sick to the Employer as soon as possible, but no later than 9 a.m. on the first day of illness. The Employee undertakes to comply with the rules related to reporting and inspection in the case of illness, as adopted from time to time by the Employer.
		

			
	
			
				 8
			

			
	
			
			Insurance

		
			The Employer will comply with the obligations under the Dutch Health Care Insurance Act.
		

			
	
			
				 9
			

			
	
			
			Pension

		
			The Employee shall be entitled to participate in the pension scheme of the Employer following company guidelines.
		

			
	
			
				 10
			

			
	
			
			Confidentiality obligation

			
	
			
				 10.1
			

			
	
			
			Both during the term of the Agreement and after the Agreement has been terminated for any reason whatsoever, the Employee shall not make any statements in any way whatsoever to anyone whomsoever (including other personnel of the Employer, unless these should be informed of anything in connection with the work they perform for the Employer), regarding matters, activities and interests of a confidential nature related to the business of the Employer and/or the Employer’s affiliates, of which the Employee became aware within the scope of his work for the Employer and the confidential nature of which he is or should be aware 

		 

 

	(“Confidential Information”). The Confidential Information includes, inter alia, information about the Employer’s products, processes and services, including but not limited to, information relating to research, development, inventions, manufacture, purchasing, engineering, marketing, merchandising and selling. 

			
	
			
				 10.2
			

			
	
			
			For all oral and written publications by the Employee, which can or could harm the interests of the Employer, prior approval from the Employer has to be obtained. This approval shall only be refused on sincere grounds based on those interests. 

			
	
			
				 10.3
			

			
	
			
			All information exchanged via the Employer’s email system is considered to be company’s proprietary information and should be taken care of accordingly.

			
	
			
				 10.4
			

			
	
			
			The Employee agrees that the confidentiality obligations set forth in this clause 10 supersede the Employee’s obligations to any other company, fund or other organization with which the Employee may have a relationship (“Affiliated Entities”) and that any Confidential Information that Employee receives will only be used within the scope of his employment under this Agreement or any successor agreement with Employer and will not be used during the course of his relationship, or communicated through by any means to, any Affiliated Entity.

			
	
			
				 11
			

			
	
			
			Documents

		
			The Employee is prohibited from in any way having documents and/or correspondence and/or other information carriers and/or copies thereof in his possession that belong to the Employer and/or to the Employer’s affiliates, with the exception of the extent to which and as long as required for the performance of his activities for the Employer. In any event, the Employee is required, even without any request being made to that end, to return such documents and/or correspondence and/or other information carriers and/or copies thereof to the Employer immediately upon the end of the Agreement, or in the event the Employee is on non-active duty for any reason whatsoever.
		

			
	
			
				 12
			

			
	
			
			Ban on ancillary jobs

		
			During the term of the Agreement, without the prior written consent of the Employer, the Employee shall not accept any paid work or time-consuming unpaid work at or for third parties and will refrain from doing business for his own account, other than as provided in clause 1.4 above. For the avoidance of doubt the Employer shall not unreasonably withhold its consent for the Employee to take on any positions at third parties should the Employee fulfill such position as a Venture Partner of Forbion Capital Partners.  
		

			
	
			
				 13
			

			
	
			
			Non-competition and business relationship clause

			
	
			
				 13.1
			

			
	
			
			Both during the term of the Agreement and for a period of one year after the Agreement has been terminated for any reason whatsoever, without the prior written consent of the Employer, the Employee shall not be engaged or involved or have any share in any manner whatsoever, directly or indirectly, whether on his own behalf or for third parties, in any enterprise which conducts activities in a field similar to or otherwise competing with that of the Employer and/or the Employer’s affiliates, nor act, in any manner whatsoever, directly or indirectly, whether on his own behalf or for third parties, as an intermediary in relation to such activities. The activities contemplated by clause 1.4 shall not be deemed to be in breach of this clause 13.1.

		
			

		 

 

		

			
	
			
				 13.2
			

			
	
			
			Both during the term of the Agreement and for a period of one year after the Agreement has been terminated for any reason whatsoever, without the prior written consent of the Employer, the Employee shall not perform or have performed professional services in connection with any product or research or development or commercialization that competes with products, or research or development or commercialization of Employer, directly or indirectly, whether on his own behalf or for third parties, nor enter into contacts,  in that respect, directly or indirectly, whether on his own behalf or for third parties, with clients and/or relations of the Employer and/or the Employer’s affiliates and/or purchasers of products and/or services of the Employer and/or the Employer's affiliates. The activities contemplated by clause 1.4 shall not be deemed to be in breach of this clause 13.2

			
	
			
				 13.3
			

			
	
			
			Clients and/or relations of the Employer and/or the Employer’s affiliates such as set out in article 13.2 of this Agreement shall in all events mean relations of the Employer and/or the Employer’s affiliates with which the Employer has or has had (business) contact in any manner whatsoever throughout the course of, or otherwise prior to the termination of, the Agreement.

			
	
			
				 13.4
			

			
	
			
			Both during the term of the Agreement and for a period of one year after the Agreement has been terminated for any reason whatsoever, without the prior written consent of the Employer, the Employee shall refrain from becoming engaged or involved in any manner whatsoever, directly or indirectly, whether on his own behalf or for third parties, in actively enticing away, taking (or causing to have taken) into employment, nor make use of, in any manner whatsoever, directly or indirectly, whether on his own behalf or for third parties, the type of work of employees or persons who in a period of one year prior to the termination of the Agreement of the Employee are or have been in the employment of the Employer and/or the Employer’s affiliates.

			
	
			
				 13.5
			

			
	
			
			Employee acknowledges and agrees to adhere to this clause as the Employer has a serious business interest in binding the Employee to the non-competition and business relationship clause, due to the fact that (i) within the organization of the Employer competition-sensitive information as well as confidential information related to the Employer and its clients and relations, such as but not limited to products, or research or development or commercialization of Employer (“Sensitive Business Information”) are available and (ii) in the position of Chief Scientific Officer and GM, Amsterdam the Employee has access to this Sensitive Business Information and/or will become aware of this Sensitive Business Information and/or will maintain (commercial) contacts with clients, suppliers, competitors etc. Given the aforesaid considerations (i) and (ii) in this clause, combined with the education and capacities of the Employee, the Employer has a well-founded fear that its business interest will be harmed substantially if the Employee performs competing activities as set forth in clauses 13.1 up to and including 13.5 of the Agreement within a period of 12 months after termination of the Agreement. 

			
	
			
				 14
			

			
	
			
			Intellectual and industrial property 

			
	
			
				 14.1
			

			
	
			
			The Employer is or will be considered to be, to the fullest extent allowed by law, the maker/producer/designer/breeder of all that which is made, created, improved, produced, designed, invented or discovered by the Employee during his activities performed for the Employer (the Works).

		
			

		 

 

		

			
	
			
				 14.2
			

			
	
			
			The Employee is obliged to fully and comprehensibly disclose all Works to the Employer in writing immediately after they are created or after the creation becomes known to the Employee, and in any case at the request of the Employer.

			
	
			
				 14.3
			

			
	
			
			The Employee hereby transfers and assigns all his rights to and in connection with the Works to the Employer in advance.

			
	
			
				 14.4
			

			
	
			
			The Employee is obliged, at first request of the Employer, to transfer and assign to the Employer all rights to and in connection with the Works that do not belong to the Employer by operation of law (van rechtswege), and that are not transferred to the Employer pursuant to article 14.3 of this Agreement. This concerns all rights, anywhere in the world, to and arising from or in connection with the Works. This obligation of the Employee remains in force even after the end of this Agreement.

			
	
			
				 14.5
			

			
	
			
			The Employee agrees to perform, to the extent necessary and/or at the request of the Employer, such further acts as may be necessary or desirable to apply for, obtain and/or maintain protection for the Works, inter alia by means of the establishment of intellectual and industrial property rights. The Employee hereby grants permission and power of attorney to the Employer to the extent necessary to carry out every required act on behalf of the Employee to obtain protection for the Works, or to transfer the Works and any rights relating thereto, to the Employer. The Employer will compensate the reasonable costs made in respect hereof, in so far as the payment that the Employee receives pursuant to article ‎3.1 of this Agreement cannot be considered as compensation for such costs. This obligation of the Employee remains in force even after the end of the Agreement.

			
	
			
				 14.6
			

			
	
			
			The Employee acknowledges that the payment ex article ‎3.1 of this Agreement includes a reasonable compensation for any possible deprivation of any intellectual and industrial property rights. To the extent legally possible, the Employee hereby waives his right to any additional compensation with respect to the Works.

			
	
			
				 15
			

			
	
			
			Gifts

		
			In connection with the performance of his duties, the Employee is prohibited from accepting or stipulating, either directly or indirectly, any commission, reimbursement or payment, in whatever form, or gifts from third parties other than those covered under article 1.4. The foregoing does not apply to standard promotional gifts having little monetary value.
		

			
	
			
				 16
			

			
	
			
			Penalty clause

		
			In the event the Employee acts in violation of any of the obligations under the articles 10 through 15 of this Agreement, the Employee shall, contrary to section 7:650 paragraphs 3, 4 and 5 Dutch Civil Code, without notice of default being required, forfeit to the Employer for each such violation, a penalty in the amount of EUR 10.000,00 as well as a penalty of EUR 1.000,00 for each day such violation has taken place and continues. Alternatively, the Employer will be entitled to claim full damages. 
		

			
	
			
				 17
			

			
	
			
			Transfer of an undertaking

		
			The Employee shall remain under the obligation to adhere the set out in the articles 10 through 16 of this Agreement vis-à-vis the Employer, if the enterprise of the Employer or a part thereof is transferred to a third party within the meaning of section 7:662 and onwards Dutch Civil 

		 

 

Code and this Agreement terminates before or at the time of such transfer, whereas in the event of continuation of the Agreement the Employee would have entered the employment of the acquirer by operation of law.
		

			
	
			
				 18
			

			
	
			
			Other arrangements

		
			Subject to the provisions in this Agreement, the arrangements related to employment conditions adopted by the Employer from time to time, as laid down in the Employee Handbook are applicable. A copy of these arrangements has been provided to the Employee. By signing this agreement, the Employee acknowledges to have received and understood the Employee Handbook and the Insider Trading Policy.
		

			
	
			
				 19
			

			
	
			
			Employment costs regulation

		
			The conditions of employment costs regulation determined by the Employer apply. In this context, the Employer reserves the right at its sole discretion to modify certain fringe benefits, without any compensation in return.
		

			
	
			
				 20
			

			
	
			
			Amendment clause 

			
	
			
				 20.1
			

			
	
			
			The Employer reserves the right to unilaterally amend the Agreement and the arrangements referred to in article 18 of this Agreement if it has such a serious interest in that respect entailing that the interests of the Employee must yield to that in accordance with standards of reasonableness and fairness.

			
	
			
				 20.2
			

			
	
			
			The Employer reserves the right to unilaterally amend the Agreement and the arrangements referred to in article 18 of this Agreement in the event of a relevant amendment of the law.

			
	
			
				 21
			

			
	
			
			Applicable law, no collective labour agreement

			
	
			
				 21.1
			

			
	
			
			This Agreement is governed by Dutch law.

			
	
			
				 21.2
			

			
	
			
			The Agreement is not subject to any collective labour agreement.

		
			

		 

 

		 

 

THIS AGREEMENT has been entered into on the date stated at the beginning of this Agreement
		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						uniQure biopharma B.V.

					
						 

					
					
						 

					
					
						uniQure biopharma B.V.

					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						/s/ Matthew Kapusta

					
					
						 

					
					
						 

				
	
					
						By: 

					
					
						Matthew Kapusta

					
					
						 

					
					
						By: 

				
	
					
						Title: 

					
					
						CEO

					
					
						 

					
					
						Title:

				

		
			 
		

		
			 
		

			
					
						Employee

				
	
					
						 

				
	
					
						 

				
	
					
						 

				
	
					
						 

				
	
					
						/s/ Sander van Deventer

					
					
						 

				
	
					
						By:    Sander van Deventer

					
					
						 

				
	
					
						 

					
					
						 

				

		
			 
		

		
			 
		

		
			
		

		
			

		 

 

		

		
			Exhibit A
		

		
			 
		

		
			Reporting to Chief Executive Officer, the Chief Scientific Officer (CSO) and General Manager,  Netherlands will be responsible for the company’s research, scientific and technology platform strategy and activities in support of the company’s portfolio strategy, including basic and applied research projects, as well as the development of new processes, technologies or products.
		

		
			 
		

		
			Additionally, the CSO will also provide guidance on scientific-related matters within the company and represent uniQure at scientific/medical conferences, as well as with investors and regulatory agencies.
		

		
			 
		

		
			Job Responsibilities:
		

		
			 
		

			
	
			
				 ·
			

			
	
			
			Develop, refine and execute uniQure’s research, scientific and technology platform strategy that supports and enhances the corporate long-term plan;

			
	
			
				 ·
			

			
	
			
			Effectively communicate a vision and plan related to new product development,  as well as scientific and technological matters;

			
	
			
				 ·
			

			
	
			
			In collaboration with the CEO, Commercial leader and Business Development leader, define a process and criteria for identifying new targets, indications and potential gene therapy product candidates;

			
	
			
				 ·
			

			
	
			
			Provide scientific guidance on strategic and operating decisions, setting strategy, and performance goals;

			
	
			
				 ·
			

			
	
			
			Regularly reporting to the Board and other members of the organization to ensure transparency regarding the progress of research and platform development programs;

			
	
			
				 ·
			

			
	
			
			Work closely with the Chief Operating Officer, Chief Medical Officer and other key leaders to ensure execution on a corporate, global strategy related to R&D and technology/platform development;

			
	
			
				 ·
			

			
	
			
			Provide strong scientific leadership for the uniQure research,  nonclinical and emerging technology development teams;

			
	
			
				 ·
			

			
	
			
			Lead the effort to translate discovery research into clinical-ready product candidates;

			
	
			
				 ·
			

			
	
			
			Establish and/or help to maintain relationships with KOLs and academic institutions, and serve as a key liaison between the company and its external scientific advisors and the investment community;

			
	
			
				 ·
			

			
	
			
			Identify collaboration opportunities to gain access to key capabilities and provide leadership in managing such collaborations, including uniQure’s key collaboration with BMS;

			
	
			
				 ·
			

			
	
			
			Provide scientific and clinical expertise in support of product and clinical development activities;

			
	
			
				 ·
			

			
	
			
			Participate in business development and in-licensing activities, including due diligence activities as required;

			
	
			
				 ·
			

			
	
			
			Participate in leadership team meetings, Board meetings and other key operating mechanisms required of senior management and by the Chief Executive Officer;

			
	
			
				 ·
			

			
	
			
			Make and attend scientific presentations, and participate in key scientific and medical conferences; 

			
	
			
				 ·
			

			
	
			
			Develop budgets for relevant functional responsibilities, subject to approval by the Chief Executive Officer and Principal Financial Officer, and ensure execution within approved targets; 

			
	
			
				 ·
			

			
	
			
			Foster and develop an innovative and productive organization of talented scientists, including the management, motivation,  recruitment and evaluation of personnel; and

			
	
			
				 ·
			

			
	
			
			Plan, organize, lead and control the daily activities of uniQure’s operation in Amsterdam

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}]]